U.S FDA approves Satralizumab for the treatment of NMOSD patients
Category: #health  By Pankaj Singh  Date: 2020-08-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

U.S FDA approves Satralizumab for the treatment of NMOSD patients

Genentech Inc., one of leading biotechnology corporations which became a subsidiary of Roche in 2009, has reportedly announced that the U.S FDA (Food and Drug Administration) has reportedly approved Satralizumab for treating adult patients with anti-aquaporin-4 antibody-positive NMOSD (Neuromyelitis Optica Spectrum Disorder).

 

NMOSD is lifelong, debilitating, and rare autoimmune disorder of the central nervous system primarily damages the spinal cord and optic nerve, causing muscle weakness, blindness, and paralysis. The approval granted to Genentech is only the second targeted treatment for NMOSD patients and the first available treatment for at-home administration.

 

Satralizumab, which is marketed under the brand name Enspryng, is the monoclonal antibody that inhibits and targets interleukin-6 receptor activity. It apparently plays a key role in the inflammation observed in NMOSD.

 

Speaking on the treatment, Jeffrey Bennett, who is the investigator for the satralizumab clinical trials said that in patients with NMOSD, relapses could cause irreversible, disabling, and devastating neurological effects. Having an approved therapy as a subcutaneous injection at home has proven to have an effect on the frequency of relapses and is a pivotal advancement for patients, he added.

 

US FDA’s approval of the treatment was based on the findings from phase 3 clinical trials named SAkuraSky and SAkuraStar for Satralizumab. These clinical trials included over 170 patients who were randomly assigned to receive placebo or satralizumab 120 mg.

 

Sources cite that all these patients received a loading dose of the Satralizumab at baseline, second week, and the fourth week, followed by four-week treatment intervals. The primary endpoint in both clinical trials was period to protocol-defined relapse.

 

Notably, both clinical trials included some patients who were anti-aquaporin-4 antibody positive and negative to precisely reflect clinical practice. The most common adverse events observed were headache, nasopharyngitis, and upper respiratory tract infection.

 

As per Genentech, Enspryng will be available in the United States within 2 weeks. The drug is already approved in Canada, Switzerland, and Japan, with the application under review in China and the European Union.

 

Source Credit - https://www.hcplive.com/view/fda-approves-neuromyelitis-optica-spectrum-disorder

 



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Dada Group partners with Ferrero for new snack food retail model
Dada Group partners with Ferrero for new snack food retail model
By Pankaj Singh

The new retail model will help Ferrero improve brand reach to younger online customers in China

Chinese on-demand delivery and retail platform, Dada Group has inked...

Aphena Pharma to complete expansion of Solid Dose Division by April
Aphena Pharma to complete expansion of Solid Dose Division by April
By Pankaj Singh

Aphena Pharma Solutions, a pharmaceutical services provider, has reportedly announced the continuous expansion of its Tennessee-based Solid Dose Division worth $21 million. This division is expected to be completed by ...

Canada-based CloudMD buys CMD to expand medical database
Canada-based CloudMD buys CMD to expand medical database
By Pankaj Singh

CloudMD Software & Services Inc., a virtual medical care solutions provider based in Canada, has reportedly announced that it has completed the acquisition of the Canadian Medical Directory (CMD)- the nation’...